Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All Ages~* Definite diagnosis of Tuberous Sclerosis according to the modified Gomez criteria~* At least one Subependymal Giant Cell Astrocytoma of at least 1 cm in diameter~* Evidence of SEGA worsening as compared to prior MRI scans~* Females of child bearing potential must use birth control~* Written informed consent~Exclusion Criteria:~* SEGA related surgery is likely to be required in the opinion of the investigator~* Recent heart attack, cardiac related chest pain or stroke~* Severely impaired lung function~* Severe liver dysfunction~* Severe kidney dysfunction~* Pregnancy or breast feeding~* Current infection~* History of organ transplant~* Surgery within two months prior to study enrollment~* Prior therapy with a medication in the same class as Everolimus~* Uncontrolled high cholesterol~* Uncontrolled diabetes~* HIV~* Patients with metal implants thus prohibiting MRI evaluations~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus (Type: EXPERIMENTAL): Everolimus was administered orally at a starting dose of 4.5mg/m\^2 daily and subsequently titrated to attain whole blood trough concentration of 5 to 15 ng/mL. Dose adjustments were permitted based on safety and whole blood trough concentrations.
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo administered orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).